Clopidogrel monotherapy proves noninferior to extended DAPT for net adverse clinical events in high-risk patients.
risk difference -0.1 percentage points
95% CI -1.3 to 1.2
P=0.001 for noninferiority
n=3,203
80 (5.0%) vs 81 (5.1%) at 24 months
Key points
Context & question:To evaluate whether clopidogrel monotherapy is noninferior to extended dual antiplatelet therapy with clopidogrel plus aspirin beyond 12 months after drug-eluting stent implantation in patients at high ischemic risk.
Methods & population:Open-label randomized noninferiority trial in South Korea (margin 2.3 pp); 3203 high-ischemic-risk patients 12 months after drug-eluting stent implantation; Clopidogrel monotherapy vs extended DAPT (clopidogrel + aspirin); 24 months follow-up.
Finding & limits:Net adverse clinical events at 24 months occurred in 80 patients with monotherapy versus 81 with extended dual antiplatelet therapy. Design limitations: open-label design, and the net composite balances ischemic and bleeding events that moved in opposite directions, so the neutral net result masks trade-offs.
Discussion
Expert perspectives 14
Author’s perspective
Prof. Byeong-Keuk KimSeverance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea
“Extended DAPT provided greater protection against major ischemic events, including death, whereas clopidogrel monotherapy reduced major or clinically relevant bleeding. It seems that no single strategy is best for every patient, but rather, long-term antiplatelet therapy should be individualised according to ischaemic and bleeding risks, clinical characteristics and treatment preferences in a shared decision-making process between patients and physicians.”
Results readout·Interventional / Structural Cardiology · Shaare Zedek Medical Center
Reports net adverse clinical events of 5.0% vs 5.1% at 24 months in 3,203 high ischaemic risk patients, which met noninferiority against a 2.3 point margin.
Notes A-CLOSE was an open label, investigator initiated trial at 19 centers in South Korea that tested stopping aspirin at 12 months in high ischemic risk patients.
My @TCTMD Beyond the Data video: A-CLOSE with @Aspirinbk and dominic angillo
How do we balance bleeding versus ischaemic risk in high risk pci? Did Asian paradox play chance in findings? #ESC2026
Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with
respect to net adverse clinical events at 24 months.
A-CLOSE — In 3,203 high-risk patients after 12 months of DAPT following PCI, clopidogrel monotherapy was non-inferior to extended dual antiplatelet therapy for net adverse clinical events at 24 months.
@escardio #ESCCongress #ESC2026 #EBM
@NEJM Another data point that “event-free to 12 months” still matters more than the original risk label. A-CLOSE shows clopidogrel monotherapy was noninferior to 3 extra years of DAPT for NACE in high-ischemic-risk DES patients — curves essentially superimposed, difference −0.1 pp.
A-CLOSE
Outstanding questions
Open questions from this trial that would benefit from expert input.
Ask about this paper
Answers are grounded in this paper and cite their sources.
Full evidence
Why the trial, tables, limitations, PICO, abstract, media & sources
Why the trial?
After high-risk PCI, extended dual antiplatelet therapy lowers ischaemic risk at the price of bleeding. Whether clopidogrel monotherapy can preserve ischaemic protection while reducing bleeding in this high-risk population had not been established.
Does clopidogrel monotherapy compared with extended DAPT improve net adverse clinical events in high-ischemic-risk patients 12 months after drug-eluting stent implantation?
View moreView less
Evidence details
What drove the result?
Outcome
Clopidogrel
DAPT
Net adverse clinical events (death, MI, ST, stroke, BARC 2/3/5) Risk difference -0.1 pp (90% CI -1.3 to 1.2); P=0.001 for noninferiority
Clopidogrel 80 (5.0%)
DAPT 81 (5.1%)
Death, MI, stent thrombosis, or stroke Key secondary - higher with monotherapy (HR 2.33, 1.47-3.69; P<0.001); opposite direction from bleeding
Clopidogrel 60 (3.7%)
DAPT 26 (1.6%)
Limitations & tradeoffs
Safety
BARC 2, 3, or 5 bleeding 28 (1.8%) vs 65 (4.1%); HR 0.43 (95% CI 0.27-0.67); P<0.001.
Design limitations
open-label design, and the net composite balances ischemic and bleeding events that moved in opposite directions, so the neutral net result masks trade-offs.
Representation
conducted only in South Korea, which may limit generalizability.
Structured PICO
Does clopidogrel monotherapy compared with extended DAPT improve net adverse clinical events in high-ischemic-risk patients 12 months after drug-eluting stent implantation?
PPopulation
3,203 patients with high-risk clinical or lesion characteristics 12 months after drug-eluting stent implantation, followed for 24 months.
IIntervention
Clopidogrel monotherapy
CComparator
Extended dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin
OOutcome
Net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding at 24 monthscomposite endpoint
Main Result
Effect estimaterisk difference -0.1 percentage points (95% CI -1.3 to 1.2)
Absolute Event Rate5% vs 5.1%
p-valuep=0.001 for noninferiority
Clopidogrel monotherapy was noninferior to extended DAPT for net adverse clinical events at 24 months in high-risk patients 12 months post-DES, driven by reduced bleeding despite increased ischemic events.
Where experts stand
Dual antiplatelet therapy evidence still forming
Experts read A-CLOSE as a technical noninferiority win that hides a real trade-off: stopping aspirin cut bleeding but let more ischemic events through, so most do not see it as a simple green light to drop aspirin.
On paper, clopidogrel alone matched continued dual antiplatelet therapy on the combined outcome in high-risk stent patients. Commentators keep pointing out that the combined result was flat only because less bleeding was offset by more heart events, and at least one prominent interventionalist reads the trade as favoring staying on both drugs. The live question is which patients, if any, should drop aspirin, and whether the result carries over beyond the South Korean population studied.
Agreement
Several clinicians make the same point: the net composite looked identical between arms, but its parts moved in opposite directions. Bleeding fell with clopidogrel alone while ischemic events rose.
4 clinicians say this directly
Still unclear
Mamas asks whether the Asian paradox played a part in the findings, which leaves open whether they apply to other populations. Alania says de-escalation must be individualised, but no one has defined who should stop aspirin. Kaul notes the control arm had fewer events than expected (5.1% observed vs 7% expected).
Implication
May support switching to clopidogrel monotherapy after 12 months to reduce bleeding; extends randomized evidence on DAPT de-escalation in high-ischemic-risk patients.
Abstract
BackgroundThe effect of clopidogrel monotherapy as compared with extended dual antiplatelet therapy (DAPT) with clopidogrel and aspirin beyond 12 months after implantation of a drug-eluting stent remains uncertain in patients at high risk for recurrent ischemic events. MethodsIn this open-label noninferiority trial conducted in South Korea, we enrolled patients with high-risk clinical or lesion characteristics in whom a drug-eluting stent had been implanted 12 months earlier and randomly assigned them, in a 1:1 ratio, to receive clopidogrel monotherapy or extended DAPT (clopidogrel plus aspirin). The primary end point was net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding at 24 months (noninferiority margin, 2.3 percentage points). Key secondary ischemic and bleeding end points were tested in a prespecified hierarchical order. ResultsOf the 3203 patients who underwent randomization, 1601 were assigned to receive clopidogrel monotherapy and 1602 to receive extended DAPT. Over the course of 24 months, a primary end-point event occurred in 80 patients (5.0%) in the monotherapy group and in 81 (5.1%) in the DAPT group (risk difference, −0.1 percentage points; 90% confidence interval [CI], −1.3 to 1.2; P=0.001 for noninferiority). Death from any cause, myocardial infarction, stent thrombosis, or stroke (the key secondary ischemic end point) occurred in 60 patients (3.7%) in the monotherapy group and in 26 (1.6%) in the DAPT group (hazard ratio, 2.33; 95% CI, 1.47 to 3.69; P<0.001). BARC type 2, 3, or 5 bleeding (the key secondary bleeding end point) occurred in 28 patients (1.8%) in the monotherapy group and in 65 (4.1%) in the DAPT group (hazard ratio, 0.43; 95% CI, 0.27 to 0.67; P<0.001). The incidence of serious adverse events was similar in the two groups. ConclusionsAmong patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months. (Funded by Chong Kun Dang and Samjin; A-CLOSE ClinicalTrials.gov number, NCT03947229.)
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Cite This Study
Lee et al. (2026) conducted an RCT in High risk for recurrent ischemic events after drug-eluting stent implantation (n=3,203). Clopidogrel monotherapy vs. Extended DAPT (clopidogrel plus aspirin) was evaluated on Net adverse clinical events, a composite of death from any cause, myocardial infarction, stent thrombosis, stroke, or Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding at 24 months (risk difference -0.1 percentage points, 95% CI -1.3 to 1.2, p=0.001 for noninferiority). Clopidogrel monotherapy was noninferior to extended DAPT for net adverse clinical events at 24 months.